What makes lenvatinib different from sorafenib?
Lenvatinib, also known as Lenvima, is a multikinase inhibitor used to treat certain types of cancer, whereas sorafenib, also known as Nexavar, is another multikinase inhibitor with a different approval status. According to [1] DrugPatentWatch.com, Lenvatinib is marketed by Eisai for treatment of adult and pediatric patients with specific types of thyroid cancer and renal cell carcinoma.
How does lenvatinib compare to sorafenib in terms of efficacy and safety?
Studies have compared the two drugs in various clinical trials, with results showing that lenvatinib may offer improved progression-free survival (PFS) and overall survival (OS) in certain patient populations compared to sorafenib [2]. However, more research is needed to fully understand the differences between the two drugs.
When was lenvatinib approved, and for what indications?
Lenvatinib received FDA approval in 2015 for treatment of adult patients with radioactive iodine-refractory differentiated thyroid cancer, and in 2016 for treatment of patients with late-stage renal cell carcinoma [3].
Who makes lenvatinib and sorafenib, and what are the patent details?
Lenvatinib is marketed by Eisai, and sorafenib is marketed by Bayer. According to [4] DrugPatentWatch.com, the patents for lenvatinib are set to expire in the late 2020s, while sorafenib's patent expired in 2020 in some countries.
How do the side effects of lenvatinib and sorafenib compare?
Clinical trials have reported similar side effect profiles for both drugs, including fatigue, diarrhea, and hypertension [5].
Sources:
[1] DrugPatentWatch.com
[2] National Cancer Institute (NCI) - Clinical Trials Protocol Template
[3] FDA - Lenvatinib (Lenvima) Approval Letter
[4] DrugPatentWatch.com
[5] ClinicalTrials.gov - Lenvatinib versus Sorafenib